Telisotuzumab Adizutecan for MET amp solid

What is the Purpose of this Study?

What happens during the study?

  • You'll get the study medicine through an IV every 3 weeks
  • Doctors will take blood and urine samples
  • You'll have regular CT or MRI scans to check your health
What is the Condition Being Studied?

Locally advanced or metastatic solid tumors that harbor MET amplification

Who Can Participate in the Study?

Who can join this study?

  • Adults who are 18 or older
  • Have a type of cancer that has spread and shows a special change called MET amplification
  • Have already tried at least one treatment for their cancer
  • Don’t have any other good treatment options that are likely to help them live longer
Age Group
Adults

What is Involved?

Why is this study happening?
Doctors are testing a new medicine called Telizotuzumab Adjzutecan (ABBV-400) to see if it is safe and works well for people with certain types of cancer that have spread and have a special change in their cells called MET amplification.

Study Details

Full Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification [M25-279]
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00118702
NCT: NCT07196644
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
INSTITUTIONAL APPROVAL SIGNOFF